gineco ro Bibliografie maternal-fetal medicine 1. Bowman JM: RhD hemolytic disease of the newborn. N Engl J Med 1998; 339:1775. 2. Diamond LE, Balkfan KD, Baty JM: Erythroblastosis fetalis and its association with universal edema of the fetus, icterus gravis neonatorium and anemia of the newborn. J Pediatr 1932; 1:269. 3. Levine P, Stetson R.: An usual case of intragroup agglutination. JA- MA 1939; 113:126. 4. Rodeck CH, Kemp JR, Holman CA, et al: Direct intravascular fetal blood transfusion by fetoscopy in severe Rhesus isoimmunisation. Lancet 1981; 1:625. 5. Bennett PR, Le Van Kim C, Colin Y, et al: Prenatal determination of fetal RhD type by DNA amplification. N Engl J Med 1993; 329:607. 6. Mari Gfor the Collaborative Group for Doppler Assesment of the Blood Velocity of Anemic Fetuses: Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. N Engl J Med 2000; 342:9. 7. Finning KM, Martin PG, Soothill PW, Avent ND: Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002; 42:1079. 8. Geifman-Holtzman O, Bernstein IM, Berry SM, et al: Fetal RhD genotyping in fetal cells flow sorted from maternal blood. Am J Obstet Gynecol 1996; 174:818. 9. van der Schoot CE, Tax GH, Rijnders RJ, et al: Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev 2003; 17:31. 10. Martin JA, Hamilton BE, Sutton PD, et al: Births: Final data for 2002. National Vital Statistics Reports 2002; 52:1. 11. Hilden JO, Gottvall T, Lindblom B.: HLA phenotypes and severe Rh(D) immunization. Tissue Antigens 1995; 46:313. 12. Ulm B, Svolba G, Ulm MR, et al: Male fetuses are particularly affected by maternal alloimmunization to D antigen. Transfusion 1999; 39:169. 13. Nicolaides KH, Thilaganathan B, Rodeck CH, Mibashan RS: Erythroblastosis and reticulocytosis in anemic fetuses. Am J Obstet Gynecol 1988; 159:1063. 14. Carritt B, Kemp TJ, Poulter M.: Evolution of the human RH (rhesus) blood group genes: a 50 year old prediction (partially) fulfilled. Hum Mol Genet 1997; 6:843. 15. Avent ND: Antenatal therapy for haemolytic disease of the fetus and newborn. In: Hadley A, Soothill P, ed. Alloimmune Disorders in Pregnancy. Anaemia, Thrombocytopenia, and Neutropenia in the Fetus and Newborn, Cambridge, UK: Cambridge University Press; 2002:121. 16. Singleton BK, Green CA, Avent ND, et al: The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative blood group phenotype. Blood 2000; 95:12. 17. Lee YL, Chiou HL, Hu SN, Wang L: Analysis of RHD genes in Taiwanese RhDnegative donors by the multiplex PCR method. J Clin Lab Anal 2003; 17:80. 18. Dunn LJ: Prevention of isoimmunization in pregnancy developed by Freda and Gorman. Obstet Gynecol Surv 1999; 54:S1. 19. Freda VJ, Gorman JG, Pollack W.: Prevention of Rh-hemolytic disease with Rhimmune globulin. Am J Obstet Gynecol 1977; 128:456. 20. Mittendorf R, Williams MA: Rho(D) immunoglobulin (RhoGAM): how it came into being. Obstet Gynecol 1991; 77:301. 21. Finn R, Clarke CA, Donohoe WT, et al: Experimental studies on the prevention of Rh haemolytic disease. Br Med J 1961; 5238:1486. 22. Bichler J, Spycher MO, Amstutz HP, et al: Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers. Transfus Med 2004; 14:165. 23. In: Brecher ME, ed. Technical Manual of the American Association of Blood Banks, ed 14. Bethesda, MD: American Association of Blood Banks; 2002:825. 24. Ness PM, Baldwin ML, Niebyl JR: Clinical high-risk designation does not predict excess fetal-maternal hemorrhage. Am J Obstet Gynecol 1987; 156:154. 25. Novaretti MC, Jens E, Pagliarini T, et al: Comparison of conventional tube test with diamed gel microcolumn assay for anti-D titration. Clin Lab Haematol 2003; 25:311. 26. Moise KJ: Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2002; 100:600. 27. Chiu RW, Murphy MF, Fidler C, et al: Determination of RhD zygosity: comparison of a double amplification refractory mutation system approach and a multiplex real-time quantitative PCR approach. Clin Chem 2001; 47:667. 28. Daniels G, Finning K, Martin P, Soothill P.: Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang 2004; 87:225. 29. Lo YM, Hjelm NM, Fidler C, et al: Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998; 339:1734. 30. Rouillac-Le Sciellour C, Puillandre P, Gillot R, et al: Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn 2004; 8:23. 31. Management of Isoimmunization in Pregnancy. American College of Obstetricians and Gynecologists Technical Bulletin 1986; 90: 32. Weiner CP, Williamson RA, Wenstrom KD, et al: Management of fetal hemolytic pag. 224 disease by cordocentesis. I. Prediction of fetal anemia [see comments]. Am J Obstet Gynecol 1991; 165:546. 33. van Kamp IL, Klumper FJ, Bakkum RS, et al: The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment. Am J Obstet Gynecol 2001; 185:668. 34. Roberts AB, Mitchell JM, Lake Y, Pattison NS: Ultrasonographic surveillance in red blood cell alloimmunization. Am J Obstet Gynecol 2001; 184:1251. 35. Opekes D, Seward G, Vandenbussche F, et al: Minimally invasive management of Rh alloimmunization: can amniotic fluid delta OD450 be replaced by Doppler studies? A prospective study multicenter trial. Am J Obstet Gynecol 2004; 191:S3. 36. Abel DE, Grambow SC, Brancazio LR, Hertzberg BS: Ultrasound assessment of the fetal middle cerebral artery peak systolic velocity: A comparison of the nearfield versus far-field vessel. Am J Obstet Gynecol 2003; 189:986. 37. Trevett T, Dorman K, Lamvu G, Moise KJ: Does antenatal maternal administration of phenobarbital prevent exchange transfusion in neonates with alloimmune hemolytic disease?. Am J Obstet Gynecol 2005; 192:478. 38. van Kamp IL, Klumper FJ, Oepkes D, et al: Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol 2005; 192:171. 39. Klumper FJ, van Kamp IL, Vandenbussche FP, et al: Benefits and risks of fetal red-cell transfusion after 32 weeks gestation. Eur J Obstet Gynecol Reprod Biol 2000; 92:91. 40. Moise KJ, Whitecar PW: Antenatal therapy for alloimmune haemolytic anemia. In: Hadley A, Soothill P, ed. Alloimmune Disorders in Pregnancy. Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn. 1, Cambridge, UK: Cambridge University Press; 2002:173. 41. Hall AM, Cairns LS, Altmann DM, et al: Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice. Blood 2005; 105:2175. 42. Hackney DN, Knudtson EJ, Rossi KQ, et al: Management of pregnancies complicated by anti-c isoimmunization. Obstet Gynecol 2004; 103:24. 43. Spong CY, Porter AE, Queenan JT: Management of isoimmunization in the presence of multiple maternal antibodies. Am J Obstet Gynecol 2001; 185:481. 44. Bowman JM, Pollock JM, Manning FA, Harman CR: Severe anti-C hemolytic disease of the newborn. Am J Obstet Gynecol 1992; 166:1239. 45. Joy SD, Rossi KQ, Krugh D, O’Shaughnessy RW: Management of pregnancies complicated by anti-E alloimmunization. Obstet Gynecol 2005; 105:24. 46. Daniels G: Blood group antibodies in hemolytic disease of the fetus and newborn. In: Hadley A, Soothill P, ed. Alloimmune Disorders in Pregnancy. Anaemia, Thrombocytopenia, and Neutropenia in the Fetus and Newborn, Cambridge, UK: Cambridge University Press; 2002:21. 47. Spence WC, Maddalena A, Demers DB, Bick DP: Prenatal determination of genotypes Kell and Cellano in at-risk pregnancies. J Reprod Med 1997; 42:353. 48. Bowman JM, Pollock JM, Manning FA, et al: Maternal Kell blood group alloimmunization. Obstet Gynecol 1992; 79:239. 49. van Dongen H, Klumper FJ, Sikkel E, et al: Non-invasive tests to predict fetal anemia in Kell-alloimmunized pregnancies. Ultrasound Obstet Gynecol 2005; 25:341. 50. Crowther C, Middleton P. Anti-D administration after childbirth for preventing Rhesus Alloimmunisation. Cochrane Database Syst. Rev. 2000; CD 000021. 51. MacKenzie IZ, Bowell P, Gregory H, Pratt G, Guest C, Entwistle CC. Routine Antenatal Rhesus D immunoglobulin prophylaxis : the results of a prospective 10 years study. Br.J.Obstet.Gynaecol. 1999; 106 : 492-497. 52. American College Of Obstetrics And Gynaecology practice bulletin. Prevention of Rh D alloimmunization. Clinical management. Guidelines for obstetricians and gynaecologists. Int J G-O 1999, 66:63-70. 53. Mannessier L, Alie-Daram S, Roubinet F. La prevention de la maladie hemolytique du fœtus et du nouveau-ne : il faut agir !! J Gynecol Obstet Biol Reprod 2000, 29 : 441-444. 54. Pernet-Mathieu F, Gaillard G. Immunisations sanguines foeto-maternelles. Rev Prat 1996, 46 : 629-636. 55. Poissonnier MH, Brossard Y et al. Incompatibilite foeto-maternelle erythrocytaire. Mises a jour en Gynecologie Obstetrique. Vigot CNGOF, Paris, 2001 : 119- 151. 56. Rossiter JP, Blakemore KJ, Kickler T. The use of polymerase chain reaction to determine fetal Rh D Status. Am J Obstet Gynecol 1994, 171: 1047-1051. 57. Wirthner D, Hohfeld P, Tissot JD. Maladie hemolytique perinatale. 1er partie: Physiopathologie; 2e partie: Prevention et prise en charge. J Obstet Gynecol Biol Reprod 1998, 27 : 135-143 et 1998, 27 : 265-276. Rouillac-Le Sciellour. 60. C, Puillandre P, Gillot R, et al: Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn 2004; 8:23. 61. Brossard Y. Cytopenies immunes neonatales. Rev Prat 2001; 51:1571-1576. 62. Immunoglobuline humaine anti-D. Prescrire 2000, 20: 650-682. Vol. 4, Nr. 4 /decembrie 2008
Vol. 4, Nr. 4/decembrie 2008 pag. 225 gineco ro
Change language